Anocca

Anocca is a private, pre-clinical stage biotech developing next-generation TCR-T cell therapies for cancer. The company has built a proprietary, integrated platform that systematically decodes T-cell biology to identify cancer-selective HLA-peptide targets and match them with optimal T-cell receptors. By focusing on the vast intracellular target space, Anocca aims to address limitations of first-generation cell therapies like CAR-T and create precision treatments for a broader range of solid and hematological cancers. Its approach combines novel engineered cell systems, high-throughput biology, and custom software analytics.

An integrated, systematic platform for TCR-T discovery combining novel engineered human cell systems (eAPC, eTP) to recreate cancer biology in vitro with a custom software ecosystem for data analysis. It is designed to identify cancer-selective HLA-peptide targets and match them with optimal T-cell receptors.

Anocca competes in the rapidly evolving TCR-T space against public companies like Adaptimmune and Immunocore, as well as numerous well-funded private biotechs and large pharma internal efforts. Differentiation relies on the efficiency and output of its proprietary discovery platform. Success depends on demonstrating a superior ability to identify novel, clinically actionable TCR-target pairs.